Revenue from operations grew by 4.18% year on year to Rs 572.64 crore in the quarter ended 31 March 2023.

Profit before tax and exceptional items stood at Rs 184.31 crore in Q4 FY23, up 27.01% from Rs 145.11 crore in the same period a year ago. The company reported an exceptional loss of Rs 19.59 crore during the quarter.

On full year basis, the pharma company's net profit increased by 1.86% YoY to Rs 623.93 crore on 7.13% decline in revenue to Rs 2,424.76 crore in FY23 over FY22.

Meanwhile, the firm's board has recommended a final dividend of Rs 35 per share and a special dividend of Rs 5 per share in view of the gain on sale of business undertaking at Thane, aggregating to total dividend of Rs 40 per share for FY23.

Pfizer is a major drug manufacturing company that focuses on a global portfolio of medical products. The company works across developed and emerging markets to advance treatments through its to segments, Pfizer Innovative Health and Pfizer Essential Health. The vast majority of the company's revenue is derived from the manufacture and sale of biopharmaceutical products. Most of the company's sales are generated by its Innovative Health segment.

Shares of Pfizer were up 0.45% to Rs 3,833.95 on the BSE.